Literature DB >> 9158825

Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins.

F W Anthony1, P W Evans, T Wheeler, P J Wood.   

Abstract

Using radioimmunoassay (RIA) and a polyclonal antibody we have shown that maternal serum vascular endothelial growth factor (VEGF) is elevated during pregnancy. In contrast, a commercial VEGF ELISA utilizing a sandwich two-site immunoassay was unable to detect VEGF in 19 of the 20 maternal serum samples analysed. In addition, the recovery of exogenous VEGF added to the pregnancy samples was low or not recordable with the ELISA. Using RIA, 82-101% of the added VEGF was recovered. These differing results could be explained by the formation of VEGF-protein complexes that are detectable using RIA but undetectable with the ELISA. Our data imply that there is a substantial increase in circulating VEGF binding proteins during pregnancy. The increase in VEGF and its binding proteins during pregnancy may reflect important physiological events in the mother and feto-placental unit.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158825     DOI: 10.1177/000456329703400309

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  13 in total

1.  Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.

Authors:  Abbie C Johnson; Erica S Hammer; Sophie Sakkaki; Sarah M Tremble; Gregory L Holmes; Marilyn J Cipolla
Journal:  Brain Behav Immun       Date:  2017-07-21       Impact factor: 7.217

2.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

3.  Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours.

Authors:  S L Sheng; S H Bao; G Huang; L M Wang
Journal:  Clin Exp Immunol       Date:  2008-03       Impact factor: 4.330

4.  Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo.

Authors:  Stacy Zamudio; Yuanhong Wu; Francesca Ietta; Alessandro Rolfo; Ashley Cross; Timothy Wheeler; Martin Post; Nicholas P Illsley; Isabella Caniggia
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

Review 5.  An unexpected tail of VEGF and PlGF in pre-eclampsia.

Authors:  David O Bates
Journal:  Biochem Soc Trans       Date:  2011-12       Impact factor: 5.407

6.  The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia.

Authors:  Eun Sung Lee; Min-Jeong Oh; Jae Won Jung; Ji-Eun Lim; Hyun-Joo Seol; Kyung-Ju Lee; Hai-Joong Kim
Journal:  J Korean Med Sci       Date:  2007-02       Impact factor: 2.153

7.  Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia.

Authors:  Victoria L Bills; Julia Varet; Ann Millar; Steven J Harper; Peter W Soothill; David O Bates
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

8.  The anti-angiogenic isoforms of VEGF in health and disease.

Authors:  Yan Qiu; Coralie Hoareau-Aveilla; Sebastian Oltean; Steven J Harper; David O Bates
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

9.  Exercise increases endostatin in circulation of healthy volunteers.

Authors:  Jian-Wei Gu; Giovani Gadonski; Julie Wang; Ian Makey; Thomas H Adair
Journal:  BMC Physiol       Date:  2004-01-16

10.  Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: a meta-analysis.

Authors:  Daye Cheng; Yiwen Hao; Wenling Zhou; Yiran Ma
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.